SNDXSyndax Pharmaceuticals Incvs its industry peers
A metric-by-metric comparison of Syndax Pharmaceuticals Inc against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SNDXThis | $1.6B#7 | — | 104.5x#12 | 9.2x#5 | 627.8%#2 | 10.5%#8 | -158.4%#10 | -1890.2%#14 | -1205.8%#6 | — | 19.8%#9 | — |
| STOK | $1.9B#1 | — | 5.4x#10 | 10.1x#6 | 404.5%#3 | 92.3%#4 | -11.2%#6 | -2.0%#6 | — | — | 27.2%#8 | — |
| SEPN | $1.8B#2 | — | 4.8x#9 | 40.1x#9 | 4174.5%#1 | 31.9%#7 | -148.6%#9 | -12.6%#8 | — | — | 174.3%#4 | — |
| XNCR | $1.8B#3 | — | 3.6x#6 | 14.6x#7 | 13.7%#10 | 60.5%#6 | -141.4%#8 | -18.3%#9 | -31.5%#5 | — | 165.0%#5 | — |
| ANIP | — | 16.4x#3 | — | — | 43.8%#6 | 510.5%#2 | 12.6%#3 | 13.1%#2 | 16.9%#2 | — | -21.0%#12 | — |
| KLRA | $1.7B#4 | — | 1.5x#2 | — | — | — | — | 0.0%#3 | — | — | — | — |
| ETON | $1.6B#5 | — | 35.0x#11 | 20.4x#8 | 104.9%#5 | -20.4%#10 | -1.1%#5 | -9.9%#7 | -1.8%#4 | 4#2 | 224.3%#2 | — |
| ANAB | $1.6B#6 | — | 125.5x#13 | 6.8x#4 | 157.0%#4 | 90.9%#5 | 20.4%#2 | -103.8%#13 | — | — | 178.2%#3 | — |
| KARD | $1.6B#8 | — | 2.5x#3 | — | — | — | — | 0.0%#3 | — | — | — | — |
| INVA | $1.5B#9 | 4.9x#2 | 1.2x#1 | 3.7x#2 | 14.7%#9 | 1059.2%#1 | 39.8%#1 | 22.0%#1 | 14.7%#3 | 5#1 | 8.8%#10 | — |
| BCAX | $1.5B#10 | — | 3.2x#5 | — | — | -102.9%#12 | — | -29.4%#10 | — | — | 106.2%#6 | — |
| XERS | $1.5B#11 | — | — | 5.1x#3 | 43.7%#7 | 101.0%#3 | 8.5%#4 | — | 20.6%#1 | — | 6.5%#11 | — |
| AVLN | $1.5B#12 | — | 3.7x#7 | — | — | — | — | 0.0%#3 | — | — | — | — |
| TYRA | $1.5B#13 | — | 4.1x#8 | — | — | -38.7%#11 | — | -33.9%#11 | — | — | 101.1%#7 | — |
| RARE | $1.4B#14 | — | — | 2.1x#1 | 20.2%#8 | -1.1%#9 | -79.5%#7 | — | — | — | -49.5%#13 | — |
| DMRA | $1.4B#15 | 3.0x#1 | 2.7x#4 | — | — | -878.8%#13 | — | -40.7%#12 | — | — | 675.3%#1 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice